Synthesis of novel 4-substituted-7-trifluoromethylquinoline derivatives with nitric oxide releasing properties and their evaluation as analgesic and anti-inflammatory agents

被引:97
作者
Abadi, AH [1 ]
Hegazy, GH [1 ]
El-Zaher, AA [1 ]
机构
[1] Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Cairo 11562, Egypt
关键词
NO-NSAID; quinoline;
D O I
10.1016/j.bmc.2005.05.053
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Six derivatives of the general formula 2- or 4-(7-trifluoromethylquinolin-4-ylamino) benzoic acid N'-(nitrooxyacetyl or propionyl) hydrazide and an oxime of the formula 1-[4-(7- trifluoromethylquinolin-4-ylamino)phenyl[ethanone oxime were synthesized and tested for their in vivo anti-inflammatory, analgesic, and ulcerogenic properties, as well as their in vitro nitric oxide release ability. Compound 2-(7-trifluoromethylquinolin-4-ylamino)benzoic acid N'-(2-nitrooxy propionyl)hydrazide 12 showed an anti-inflammatory activity comparable to that of indomethacin in the carrageenan-induced rat paw edema test, and equipotency to glafenine in the acetic acid mice induced writhing model at 100 mg/kg p.o., respectively. All the final compounds showed no tendency to induce stomach ulceration in rats; nitric oxide seems to contribute to their excellent safety profile. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5759 / 5765
页数:7
相关论文
共 23 条
[1]  
Abadi AH, 1998, ARCH PHARM, V331, P319, DOI 10.1002/(SICI)1521-4184(199810)331:10<319::AID-ARDP319>3.3.CO
[2]  
2-M
[3]  
ALLAIS A, 1973, CHIM THER, V8, P154
[4]   The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: Results from a randomized, controlled trial [J].
Bias, P ;
Buchner, A ;
Klesser, B ;
Laufer, S .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (04) :611-618
[5]   Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin [J].
Cena, C ;
Lolli, ML ;
Lazzarato, L ;
Guaita, E ;
Morini, G ;
Coruzzi, G ;
McElroy, SP ;
Megson, IL ;
Fruttero, R ;
Gasco, A .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (05) :747-754
[6]   The safety of lumiracoxib when used in the treatment of arthritis [J].
Doggrell, SA .
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (02) :347-350
[7]   Adverse cardiovascular effects of the coxibs [J].
Dogné, JM ;
Supuran, CT ;
Pratico, D .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) :2251-2257
[8]   Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs:: Defining the role of gastroprotective agents [J].
Hunt, RH ;
Barkun, AN ;
Baron, D ;
Bombardier, C ;
Bursey, FR ;
Marshall, JR ;
Morgan, DG ;
Paré, P ;
Thomson, ABR ;
Whittaker, S .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 16 (04) :231-240
[9]  
Insel PA, 1996, PHARMACOL BASIS THER, P617
[10]   Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs [J].
Keeble, JE ;
Moore, PK .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (03) :295-310